P3 Health Partners Inc. Class A (PIII)

The company's stock was trading at $3.49 at the beginning of 2026 and has since increased by 1.7% to $3.55 as of May 9, 2026. The share price as of May 1, 2026, was $2.93, representing a significant decline of 66.67% compared to May 5, 2025. Key financial announcements include the Third Quarter 2025 Results, Fourth Quarter and Full Year 2025 Results, and 2026 Guidance. Analysts have revised price targets downward, citing weaker-than-expected Q3 aEBITDA, but maintain optimism for long-term improvement. A 1-50 reverse stock split occurred before market open on Monday, April 14, 2025.

There is no specific information provided about the demand seasonality for P3 Health Partners' products and services. Demand for healthcare services might exhibit some seasonal variations related to enrollment periods or higher incidence of certain illnesses during specific times of the year, but this is not explicitly detailed for P3 Health Partners.

P3 Health Partners Inc. is a patient-centered and physician-led population health management company providing value-based care through a network of local physicians. The company aggregates and supports existing community healthcare resources to build a network of providers who collaborate to deliver coordinated and integrated care. P3 Health Partners operates within the Healthcare sector, specifically in the Medical Care Facilities and Offices and Clinics of Medical Doctors industries. The company's primary services are its comprehensive value-based care coordination and administrative services, which support primary care providers in managing the care of Medicare Advantage patients, leveraging a proprietary technology platform.

As of December 31, 2024, P3 Health Partners had expanded its operations to 27 markets across five states: Arizona, California, Nevada, and Oregon. By the end of 2024, P3 had grown its network to approximately 3,100 primary care physicians and served approximately 123,800 at-risk members. The company utilizes an affiliate model to quickly enter new markets by partnering with existing local physicians and leveraging local healthcare infrastructure.

Direct information regarding specific events that have explicitly affected P3 Health Partners' brand reputation in the past year is limited. Analysts have trimmed price targets due to weaker-than-expected Q3 aEBITDA, but some maintain optimism for long-term improvement. The significant decline in stock price over the past year could also be perceived negatively by investors and potentially impact reputation. The company's focus on operational progress and a clear path to profitability in 2026 suggests efforts to strengthen its standing.

P3 Health Partners' ownership is a mix of institutional shareholders, insiders, and public shareholders. Major institutional owners include Alyeska Investment Group, L.P., Vanguard Group Inc., and BlackRock, Inc. Significant individual and insider owners include Chicago Pacific Founders Ugp LLC, Sherif Abdou, and Michael Balkin. Insider ownership represents a substantial portion of the company's equity.